Shi, W.; Cao, X.; Liu, Q.; Zhu, Q.; Liu, K.; Deng, T.; Yu, Q.; Deng, W.; Yu, J.; Wang, Q.;
et al. Hybrid Membrane-Derived Nanoparticles for Isoliquiritin Enhanced Glioma Therapy. Pharmaceuticals 2022, 15, 1059.
https://doi.org/10.3390/ph15091059
AMA Style
Shi W, Cao X, Liu Q, Zhu Q, Liu K, Deng T, Yu Q, Deng W, Yu J, Wang Q,
et al. Hybrid Membrane-Derived Nanoparticles for Isoliquiritin Enhanced Glioma Therapy. Pharmaceuticals. 2022; 15(9):1059.
https://doi.org/10.3390/ph15091059
Chicago/Turabian Style
Shi, Wenwan, Xia Cao, Qi Liu, Qin Zhu, Kai Liu, Tianwen Deng, Qingtong Yu, Wenwen Deng, Jiangnan Yu, Qilong Wang,
and et al. 2022. "Hybrid Membrane-Derived Nanoparticles for Isoliquiritin Enhanced Glioma Therapy" Pharmaceuticals 15, no. 9: 1059.
https://doi.org/10.3390/ph15091059
APA Style
Shi, W., Cao, X., Liu, Q., Zhu, Q., Liu, K., Deng, T., Yu, Q., Deng, W., Yu, J., Wang, Q., & Xu, X.
(2022). Hybrid Membrane-Derived Nanoparticles for Isoliquiritin Enhanced Glioma Therapy. Pharmaceuticals, 15(9), 1059.
https://doi.org/10.3390/ph15091059